Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3111-3121

  Lee, Dae Ho ^a   Lee, Jung Shin ^a   Kim, Sang We ^a   Rodrigues Pereira, José ^b   Han, Baohui ^c   Song, Xiang Qun ^d   Wang, Jie ^e   Kim, Hoon Kyo ^f   Sahoo, Tarini Prasad ^g   Digumarti, Raghunadharao ^h   Wang, Xin ⁱ   Altug, Sedat ⁱ   Orlando, Mauro ⁱ  

^a Asan Medical Center   (South Korea)

^b Grupo Assistência Médica   (Brazil)

^c SHANGHAI CHEST HOSPITAL   (China)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^f The Catholic University of Korea   (South Korea)

^g Chirayu Medical College and Hospital   (India)

^h NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Erlotinib; Never smoker; Non small cell lung cancer; Pemetrexed; Phase 2

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; PEMETREXED; TRACEVA; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE;

ERLOTINIB; NEVER SMOKER; NON-SMALL CELL LUNG CANCER; PEMETREXED; PHASE 2;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES;

EID: 84884906715     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.035     Document Type: Article

References (30)

1. S. Chattopadhyay, R.G. Moran, and I.D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol Cancer Ther 6 2007 404 417
2. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
3. G. Scagliotti, T. Brodowicz, and F.A. Shepherd Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
4. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
5. A. Bezjak, D. Tu, and L. Seymour Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 24 2006 3831 3837
6. V.A. Miller, M.G. Kris, and N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
7. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
8. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
9. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
10. D. Pham, M.G. Kris, and G.J. Riely Use of cigarette smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas J Clin Oncol 24 2006 1700 1704
11. T. Li, Y.H. Ling, I.D. Goldman, and R. Perez-Soler Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 2007 3413 3422
12. E. Giovannetti, C. Lemos, and C. Tekle Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Mol Pharmacol 73 2008 1290 1300
13. A.M. Davies, C. Ho, and L. Beckett Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation J Thorac Oncol 4 2009 862 868
14. M. Ranson, M. Reck, and A. Anthoney Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study Ann Oncol 21 2010 2233 2239
15. J. Von Pawel, Z. Papai-Szekely, and N. Vinolas A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC J Clin Oncol 29 Suppl. 2011 (abstr. 7526)
16. Y.M. Chen, W.C. Fan, and C.M. Tsai A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy J Thorac Oncol 6 2011 1110 1116
17. C.G. Azzoli, S. Baker Jr., and S. Temin American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer J Clin Oncol 27 2009 6251 6266
18. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
19. R.S. Herbst, G. Giaccone, and J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
20. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
21. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
22. P.A. Jänne, X. Wang, and M.A. Socinski Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial J Clin Oncol 30 17 2012 2063 2069
23. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2009 521 529
24. L. Zhang, M. Shenglin, and X. Song Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804) J Clin Oncol 29 2011 S7511
25. T.S. Mok, Y.L. Wu, and C.J. Yu Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 2009 5080 5087
26. W. Brugger, N. Triller, and M. Blasinska-Morawiec Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small cell lung cancer J Clin Oncol 29 2011 4113 4120
27. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
28. C. Zhou, Y.L. Wu, and G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
29. R. Rosell, E. Carcereny, and R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 3 2012 239 246
30. N. Yoshimura, K. Matsuura, and S. Mitsuoka Gefitinib (G) and pemetrexed (PEM) as a first line treatment in patients with EGFR mutant advanced non-small cell lung cancer (NSCLC): a phase II study Ann Oncol 23 Suppl. 9 2012 ix412 (abstr. 1258P)